Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of BI 1356 as Monotherapy or in Combination in Type 2 DM
This study is ongoing, but not recruiting participants.
First Received: August 14, 2008   Last Updated: October 12, 2009   History of Changes
Sponsor: Boehringer Ingelheim Pharmaceuticals
Information provided by: Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00736099
  Purpose

The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.

The treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as BI 1356 in monotherapy (patients in 1218.16 trial), BI 1356 in combination with pioglitazone (patients in 1218.15 trial), BI 1356 added to metformin background (patients in 1218.17 trial) or BI 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: BI 1356
Drug: Pioglitazone
Phase III

Study Type: Interventional
Study Design: Treatment, Parallel Assignment, Safety Study
Official Title: A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 1356 (5 mg) as Monotherapy or in Combination With Other Antidiabetic Medications in Type 2 Diabetic Patients.

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Primary Outcome Measures:
  • To investigate the long term safety and tolerability of BI 1356 given for 78 weeks as monotherapy or as combination therapy with pioglitazone, metformin, sulphonylurea or metformin plus sulphonylurea as background therapy in T2DM [ Time Frame: 78 weeks ]

Secondary Outcome Measures:
  • Incidence and intensity of AEs. Withdrawal due to AEs. Clinically relevant new or worsening findings in physical examination and ECG as reported as AE. Changes from baseline in vital signs and clininical laboratory assessment. [ Time Frame: 78 weeks ]

Estimated Enrollment: 2121
Study Start Date: August 2008
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 82 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  1. Signed and dated written informed consent in accordance with the GCP and local legislation.
  2. Patients completing the entire treatment period as a double blind trial whether or not they have been treated with rescue medication.

Exclusion Criteria:

  1. Patients who meet one or more of the withdrawal criteria of the treatment period of the previous trial.
  2. Pre-menopausal women (last menstruation =< 1 year prior to signing informed consent) who:

    • are nursing or pregnant,
    • or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of birth control) and vasectomised partners. No exception will be made.
  3. Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation.
  4. Drug abuse which, in the opinion of the investigator, would interfere with trial participation.
  5. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00736099

  Show 234 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim Pharmaceuticals
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair )
Study ID Numbers: 1218.40, EudraCT Nº: 2008-000750-13
Study First Received: August 14, 2008
Last Updated: October 12, 2009
ClinicalTrials.gov Identifier: NCT00736099     History of Changes
Health Authority: Argentina: A.N.M.A.T. (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica);   Austria: Bundesamt für Sicherheit im Gesundheitswesen, A-1030 Vienna;   Belgium: Federal Agency for Medicines and Health Products;   Canada: Health Canada, Therapeutic Products Directorate;   China: State Food and Drug Administration;   Croatia: Croatian Institute for Medicines Control, HR-10000 Zagreb;   Czech Republic: State Institute for Drug Control (SUKL), CZ-100 41 Prague 10;   Finland: Finnish Medicines Agency;   Germany: Bundesinstitut fuer Arzneimittel und Medizinprodukte (BfArM), Kurt-Georg-Kiesinger-Allee 3, D-53175 Bonn;   Great Britain: Medicines and Healthcare products Regulatory Agency (MHRA);   Greece: National Organization of Medicines (EOF) National Ethics Committee;   Hungary: National Institute of Pharmacy, H-1051 Budapest;   India: Drug Control General of India;   Israel: Ministry of Health;   Italy: Comitato di Bioetica Azienda Ospedaliero - Universitaria Pisana - PISA;   Japan: Ministry of Health, Labor and Welfare;   Korea, Republic of: Korea Food and Drug Administration;   Malaysia: Drug Control Authority;   Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS);   Netherlands: Centrale Commissie Mensgebonden Onderzoek;   New Zealand: Multi-Regional Ethics Committee / Medsafe;   Philippines: Bureau of Food and Drug;   Poland: Registration Medicinal Product Medical Device Biocidal Product;   Romania: National Medicines Agency, Bucharest;   Russia: Ministry of Healthcare and Social Development of Russian Federation, Moscow;   Slovakia: SUKL (state institute for drug control), SK-825 08 Bratislava 26;   Spain: Agencia Espanola del Medicamento y Productos Sanitarios;   Sweden: Sweden; Läkemedelsverket (Medical Product Agency) Region Etics Committee of Lund;   Taiwan: Department of Health, Executive Yuan, Taiwan;   Thailand: Thai Food and Drug Administration;   Ukraine: Ministry of Health Care of Ukraine (MoH of Ukraine);   United States: Food and Drug Administration

Additional relevant MeSH terms:
Hypoglycemic Agents
Metabolic Diseases
Pioglitazone
Physiological Effects of Drugs
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2009